A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Recent preclinical study has suggested a potential possibility that imatinib might promote
tumor growth in the presence of secondary resistance mutations [10]. This result imply that
intermittent dosing schedule of imatinib rechallenge might be better than continuous dosing
schedule in terms of controlling tumors harboring secondary resistance mutations. In
addition, in these heavily pretreated patients, even mild grade of toxicity may significantly
impair quality of life, and intermittent dosing schedule may have an advantage in this
context. Therefore, investigators hypothesize that intermittent dosing schedule of imatinib
rechallenge might be feasible and effective in patients with TKI-refractory GISTs. This study
will assess the feasibility of intermittent imatinib dosing schedule in patients with GISTs
who had failures from both imatinib and sunitinib.